Compare QSI & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | QSI | SGMT |
|---|---|---|
| Founded | 2013 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 165.6M | 169.4M |
| IPO Year | 2020 | 2021 |
| Metric | QSI | SGMT |
|---|---|---|
| Price | $0.81 | $10.86 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | $1.00 | ★ $26.13 |
| AVG Volume (30 Days) | ★ 3.2M | 1.3M |
| Earning Date | 05-07-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 28.17 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,436,000.00 | $2,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $618.07 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.69 | $4.50 |
| 52 Week High | $3.10 | $11.15 |
| Indicator | QSI | SGMT |
|---|---|---|
| Relative Strength Index (RSI) | 52.92 | 65.37 |
| Support Level | $0.70 | $6.55 |
| Resistance Level | $1.06 | $11.15 |
| Average True Range (ATR) | 0.07 | 0.61 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 53.26 | 61.85 |
Quantum-Si Inc is a life sciences company focused on proteomics research and analytical technologies. It develops single-molecule detection platforms designed to enable next-generation protein sequencing (NGPS) and large-scale protein analysis. Its technology supports massively parallel sequencing of proteins and can also be applied to the study of nucleic acids, providing tools for researchers and clinical applications in molecular analysis. The company's revenue is derived from sales of products and services.
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.